Výsledky vyhledávání - "Keith Bowering"

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes

Autor: Karen Salvesen-Sykes, Johan Ejstrud, Milivoj Piletič, Keith Bowering, James Snyder, Anne L. Peters

Publikováno v: Diabetes, Obesity & Metabolism

This post hoc analysis of an 18‐week randomized trial explored the utility of calculating baseline glycated haemoglobin (HbA1c), postprandial glucose (PPG) increments and nocturnal glucose change in predicting efficacy and safety outcomes in respon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50129bb6875dfe7b8759a0256dde97d
https://doi.org/10.1111/dom.13729

Zobrazit plný text záznamu

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis

Autor: Keith Bowering, David Russell-Jones, Simon Heller, Stewart B. Harris, Bruce W. Bode, Vincent Woo, Milivoj Piletič, Claus Dethlefsen, Chantal Mathieu, Helena W. Rodbard, Vinay Babu

Publikováno v: Diabetes Therapy

Introduction The aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin aspart (faster aspart) relative to insulin aspart (IAsp) or basal-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf57aa430fdf5eb760426339a1f2c02a
https://doi.org/10.1007/s13300-018-0553-7

Zobrazit plný text záznamu

Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial

Autor: Keith Bowering, Bruce W. Bode, Mike Sampson, John N Harvey, Rikke Beck Bang, Ditte-Marie Bretler, Michael L. Reeves, Robert Strzinek, Christopher Case

Publikováno v: Diabetes Care. 40:951-957

OBJECTIVE This multicenter, double-blind, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in adults with type 2 diabetes receiving basal insulin and oral anti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69dcc023be17cb23e5bb9f6f18afcab4
https://doi.org/10.2337/dc16-1770

Zobrazit plný text záznamu

Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes

Autor: John N Harvey, Keith Bowering, J. W. Snyder, Bruce W. Bode, J. W. Kolaczynski

Publikováno v: Diabetic Medicine

Aim This post hoc analysis explored whether mealtime fast‐acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin. Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c9e9defb606fd96c6660c73eea7035
https://pubmed.ncbi.nlm.nih.gov/30466191

Zobrazit plný text záznamu

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

Autor: Kristine Buchholtz, Thomas R. Pieber, Simon Heller, Keith Bowering, Andreas Liebl, Philip Raskin, Anders Gorst-Rasmussen

Publikováno v: Diabetic Medicine

Aims To investigate the impact of baseline 1,5‐anhydroglucitol on the treatment effect of basal–bolus therapy in people with Type 2 diabetes. Methods Post hoc analysis of onset 3, an 18‐week, randomized, phase 3 trial evaluating the efficacy an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad8560737cb1508214647033c4d78fe
https://pubmed.ncbi.nlm.nih.gov/29802636

Zobrazit plný text záznamu

Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957

Autor: Keith Bowering, Bruce W. Bode, David Russell-Jones

Publikováno v: Diabetes care. 41(3)

We appreciate the relevant comments raised by Wu et al. (1) regarding the challenges faced by clinicians in safely achieving postprandial, and overall, glycemic control for patients with diabetes in the face of individual needs and physiological vari

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca99074dc9dc7bf714ea0755a3e2fd5
https://pubmed.ncbi.nlm.nih.gov/29463669

Zobrazit plný text záznamu

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Autor: K Rohwedder, S Matthaei, Keith Bowering, Jennifer Sugg, Eva Johnsson, Shamik Parikh

Publikováno v: Diabetes, Obesity and Metabolism. 17:1075-1084

Aims To evaluate the safety and efficacy of dapagliflozin as add-on therapy to metformin plus sulphonylurea over 52 weeks. Methods Patients with type 2 diabetes mellitus (T2DM) using sulphonylurea and metformin received dapagliflozin 10 mg/day or pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc20314351d6bbbd3bd0ee2fb638801c
https://doi.org/10.1111/dom.12543

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání